How spaceflight challenges human cardiovascular health
- PMID: 35148376
- DOI: 10.1093/eurjpc/zwac029
How spaceflight challenges human cardiovascular health
Abstract
The harsh environmental conditions in space, particularly weightlessness and radiation exposure, can negatively affect cardiovascular function and structure. In the future, preventive cardiology will be crucial in enabling safe space travel. Indeed, future space missions destined to the Moon and from there to Mars will create new challenges to cardiovascular health while limiting medical management. Moreover, commercial spaceflight evolves rapidly such that older persons with cardiovascular risk factors will be exposed to space conditions. This review provides an overview on studies conducted in space and terrestrial models, particularly head-down bedrest studies. These studies showed that weightlessness elicits a fluid shift towards the head, which likely predisposes to the spaceflight-associated neuro-ocular syndrome, neck vein thrombosis, and orthostatic intolerance after return to Earth. Moreover, cardiovascular unloading produces cardiopulmonary deconditioning, which may be associated with cardiac atrophy. In addition to limiting physical performance, the mechanism further worsens orthostatic tolerance after return to Earth. Finally, space conditions may directly affect vascular health; however, the clinical relevance of these findings in terms of morbidity and mortality is unknown. Targeted preventive measures, which are referred to as countermeasures in aerospace medicine, and technologies to identify vascular risks early on will be required to maintain cardiovascular performance and health during future space missions.
Keywords: Postflight orthostatic intolerance; Spaceflight Associated Neuroocular syndrome; cardiac atrophy; cardiovascular remodelling; commercial spaceflight; countermeasure; microgravity; neck vein thrombosis.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest: J.J. has served as a consultant for Novartis, Boehringer-Ingelheim, and Novo-Nordisk and is cofounder of Eternygen GmbH. The other authors declare that they have no conflict of interest.
Comment in
-
Space: the final frontier?Eur J Prev Cardiol. 2022 Aug 5;29(10):1396-1398. doi: 10.1093/eurjpc/zwac125. Eur J Prev Cardiol. 2022. PMID: 35711101 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous